Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

BACKGROUND: Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis. Efalizumab is approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults in more than 50 countries. OBJECTIVES: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonardi, C, Menter, A, Hamilton, T, Caro, I, Xing, B, Gottlieb, AB
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408637/
https://www.ncbi.nlm.nih.gov/pubmed/18373710
http://dx.doi.org/10.1111/j.1365-2133.2008.08548.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408637/
https://www.ncbi.nlm.nih.gov/pubmed/18373710
http://dx.doi.org/10.1111/j.1365-2133.2008.08548.x

Ejemplares similares